![]() 14.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Comparatively, 39.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. Insider and Institutional OwnershipĦ1.7% of Mineralys Therapeutics shares are owned by institutional investors. Given Mineralys Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Mineralys Therapeutics is more favorable than its rivals. As a group, “Pharmaceutical preparations” companies have a potential upside of 70.60%. The acquisition of Horizon will drive growth in Amgen's revenue and non-GAAP EPS and is expected to be accretive from 2024.Mineralys Therapeutics presently has a consensus price target of $36.00, indicating a potential upside of 347.76%. Additionally, the potential new medicines in Horizon's pipeline strongly complement our own R&D portfolio. “Amgen's decades of leadership in inflammation and nephrology, combined with our global presence and world-class biologics capabilities, will enable us to reach many more patients with first-in-class medicines like TEPEZZA, KRYSTEXXA and UPLIZNA. "The acquisition of Horizon is a compelling opportunity for Amgen and one that is consistent with our strategy of delivering long-term growth by providing innovative medicines that address the needs of patients who suffer from serious diseases,” Amgen Chairman and CEO Robert A. The deal will generate cash flow of $10 billion combined over twelve months through Q3 2022, the announcement said. In addition, the two companies together will utilize Amgen’s research and development, process development and global manufacturing expertise in biologic medicines to benefit Horizon's approved medicines and potential new medicines. ![]() Amgen is aligned with that commitment and passion and will continue to the value of the current portfolio and pipeline and accelerate the ability to reach more patients globally."Īccording to Amgen, the deal will strengthen its portfolio of innovative therapeutics with complementary medicines from Horizon that address the needs of patients with rare diseases. These accomplishments are all rooted in our employees' deep commitment, dedication and personal passion for those impacted by rare, autoimmune and severe inflammatory diseases. “We have accomplished a tremendous amount for patients, their families and our customers, and created significant value for shareholders. "In nearly 15 years, we have built one of the fastest growing and most respected companies in the biotechnology industry from the ground up,” President and CEO of Horizon Therapeutics Tim Walbert said in a statement. It is one of the biggest healthcare deals announced in 2022. The deal brings together Amgen––which is focused on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation––and Horizon, which develops medicines for rare, autoimmune and severe inflammatory diseases. ![]() 29, 2022, and a premium of 19.7% above the closing price of $97.29 on Dec. That’s a premium of 47.9% above the closing price of $78.76 per share on Nov. American biopharmaceutical company Amgen is acquiring Horizon Therapeutics, a biopharmaceutical company based in Dublin, for $27.8 billion.Īmgen’s newly created subsidiary, Pillartree Limited, will acquire Horizon Therapeutics for $116.50 per share in cash.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |